Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025.

Beta Bionics Tumbles 32% on Analyst Downgrade - Orange County Business Journal

Shares in Beta Bionics Inc. are down 32% after reporting preliminary fourth quarter results. Despite revenue of $32 million coming in above the average consensus estimate of $28.9 million, the company’s new patient starts, a key metric, for its automated insulin delivery system fell short of expectations. BofA Securities downgraded Beta from Buy to Neutral and lowered its price target to $28 from $33 following the announcement, according to Drug…

Analysts downgrade Beta Bionics on new patient starts miss

Analysts downgraded Beta Bionics (Nasdaq:BBNX) to “Neutral” following preliminary fourth-quarter results that fell shy of expectations. Shares of BBNX fell 35% to $20.86 apiece in early-morning trading today. Beta Bionics, which has completed its first full year as a public company following its IPO last year, pre-announced fourth-quarter revenues of $32 million. That came in ahead of projections for $28.9 million in sales and marked a 56% year-…